Genesis Molecular AI
Category: AI in Biotech / Drug Discovery
An AI-driven drug discovery company creating novel therapeutics for severe diseases. The company's GEMS AI platform predicts molecular properties to accelerate the identification of potent and selective drug candidates. Genesis Molecular AI was founded in 2019. The company is led by Evan Feinberg, Ph.D.. Based in Burlingame, California, USA. Total funding raised: $304 million. Latest round: Series B. Key investors include Andreessen Horowitz (a16z), T. Rowe Price Associates, Radical Ventures, Fidelity Management & Research Company, Bain Capital.
- Founded
- 2019
- Headquarters
- Burlingame, California, USA
- Total funding
- $304 million
Value proposition
Dramatically accelerates the discovery of new medicines by using AI to solve complex molecular design challenges, thereby reducing the time, cost, and risk associated with traditional R&D.
Products and solutions
GEMS (Genesis Exploration of Molecular Space) AI Platform, Internal pipeline of small molecule drug candidates in areas like oncology and inflammatory diseases.
Unique value
The core innovation is the GEMS (Genesis Exploration of Molecular Space) AI platform, which uniquely combines 3D structure-aware deep neural networks and large-scale molecular simulations.
Target customer
Internal drug development pipeline and major pharmaceutical companies through strategic partnerships.
Industries served
Pharmaceuticals, Biotechnology, Life Sciences
Technology advantage
Proprietary GEMS AI platform has demonstrated success in creating novel drug candidates for challenging and previously undruggable targets, attracting major pharmaceutical partners.
How they differentiate
Genesis Therapeutics emphasizes a deep integration of its AI platform with an experienced team of medicinal chemists and clinical developers, creating a unified approach to tackle challenging drug targets.
Main competitors
Recursion Pharmaceuticals, Insilico Medicine, Schrödinger, BenevolentAI
Key partnerships
Gilead Sciences, Incyte, Eli Lilly, Genentech, Washington University in St. Louis
Notable customers
Gilead Sciences, Incyte, Eli Lilly, Genentech
Major milestones
Rebranded as Genesis Molecular AI in October 2025., Launched Pearl, a generative foundation model for biomolecular structure prediction (Oct 2025)., Announced strategic collaboration with Gilead Sciences (Sep 2024)., Announced strategic collaboration with Incyte (Feb 2025), expanded with $120M upfront (May 2026)., Raised a $200M Series B funding round in August 2023., Initiated a multi-target collaboration with Eli Lilly in 2022., Named one of Fierce Biotech's "Fierce 15" of 2020.
Growth metrics
Secured two major partnerships with Genentech and Eli Lilly, each potentially worth over $600 million. Rapidly expanded leadership team with seasoned pharma executives.
Market positioning
A leading, well-funded AI drug discovery company with a hybrid strategy of developing its own internal pipeline and pursuing high-value external partnerships.
Geographic focus
Primarily North America, with global partnerships.
Patents and IP
The company's technology is proprietary; specific patent filings are not detailed in public-facing materials.
About Evan Feinberg, Ph.D.
Evan Feinberg is a scientist and entrepreneur with a Ph.D. in Chemistry from Stanford University. He is the Co-Founder and CEO of Genesis Therapeutics, a company that leverages AI for drug discovery and development. His experience includes a deep learning consultancy at Merck and an internship at Schrödinger, showcasing his expertise at the intersection of chemistry, deep learning, and drug development.
More AI in Biotech / Drug Discovery companies
Official website: https://genesis.ml/